Last Tuesday Arkansas Attorney General, Dustin McDaniel, filed a brief supported by his counterparts in 35 other states requesting that the Arkansas Supreme Court uphold a $1.2 billion fine levied against Johnson & Johnson and a subsidiary over the marketing of the antipsychotics drug Risperdal.
While those marketing Risperdal claim to have done so responsibly, those siding with McDaniel believe that drug makers downplayed and concealed risks associated with taking the drug. Johnson & Johnson and its subsidiary, Janssen, have appealed to the Supreme Court, but McDaniel and supporters are calling on the Justices to reject the companies’ appeal.
In the brief, McDaniel wrote, “If accepted, it would effectively immunize false advertising and false labeling of drug products from regulation.”
For more information, please see: